Calamos Wealth Management LLC Has $13.41 Million Stock Position in Stryker Corporation $SYK

Calamos Wealth Management LLC raised its stake in Stryker Corporation (NYSE:SYK) by 4.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,269 shares of the medical technology company’s stock after acquiring an additional 1,448 shares during the quarter. Calamos Wealth Management LLC’s holdings in Stryker were worth $13,408,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Stryker by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after purchasing an additional 440,607 shares during the last quarter. State Street Corp raised its position in shares of Stryker by 1.0% during the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock worth $5,929,765,000 after acquiring an additional 150,204 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Stryker by 1.1% during the second quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after acquiring an additional 79,654 shares during the period. Alliancebernstein L.P. boosted its holdings in Stryker by 307.6% in the second quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock valued at $2,214,146,000 after acquiring an additional 4,223,366 shares during the last quarter. Finally, Norges Bank acquired a new stake in Stryker in the second quarter worth about $1,882,173,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK stock opened at $354.20 on Wednesday. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The firm has a fifty day moving average of $362.68 and a 200-day moving average of $376.10. The firm has a market capitalization of $135.45 billion, a price-to-earnings ratio of 46.54, a price-to-earnings-growth ratio of 2.50 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The business had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the business posted $2.87 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. On average, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. This is an increase from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio is 44.15%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SYK. Rothschild & Co Redburn initiated coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. Truist Financial lowered their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Redburn Partners set a $420.00 price target on Stryker in a research report on Thursday, September 18th. Finally, UBS Group set a $408.00 price objective on Stryker in a research note on Monday, October 13th. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $431.84.

Insider Buying and Selling at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.20% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.